Cancer Cell International,
Год журнала:
2022,
Номер
22(1)
Опубликована: Дек. 28, 2022
Abstract
Cancer
is
a
heterogeneous
disease
with
multifaceted
drug
resistance
mechanisms
(e.g.,
tumour
microenvironment
[TME],
heterogeneity,
and
immune
evasion).
Natural
products
are
interesting
repository
of
bioactive
molecules,
especially
those
anticancer
activities.
Prodigiosin,
red
pigment
produced
by
Serratia
marcescens
,
possesses
inherent
characteristics,
showing
antitumour
activities
in
different
cancers
breast,
gastric)
low
or
without
harmful
effects
on
normal
cells.
The
present
review
discusses
the
potential
role
prodigiosin
modulating
reprogramming
metabolism
various
cells
TME,
such
as
T
B
lymphocytes,
tumour-associated
macrophages
(TAMs),
natural
killer
(NK)
cells,
dendritic
(TADCs),
myeloid-derived
suppressor
(MDSCs)
which
turn
might
introduce
an
immunomodulator
cancer
therapy.
Frontiers in Immunology,
Год журнала:
2025,
Номер
15
Опубликована: Янв. 7, 2025
Gastric
cancer
is
a
common
malignant
tumor
of
the
digestive
tract,
and
its
treatment
remains
significant
challenge.
In
recent
years,
role
various
immune
cells
in
microenvironment
progression
has
gained
increasing
attention.
Immunotherapy,
primarily
based
on
checkpoint
inhibitors,
notably
improved
prognosis
patients
with
gastric
cancer;
however,
challenges
regarding
therapeutic
efficacy
persist.
Histological
features
within
microenvironment,
such
as
tertiary
lymphoid
structures
(TLSs),
tumor-infiltrating
lymphocytes,
proportion
intratumoral
stroma,
are
emerging
potentially
effective
prognostic
factors.
cancer,
TLSs
may
serve
local
hubs,
enhancing
ability
to
interact
recognize
antigens,
which
closely
linked
effectiveness
immunotherapy
survival
rates
patients.
However,
specific
cell
type
driving
TLS
formation
tumors
not
yet
been
elucidated.
Mature
B-cell
regions
containing
germinal
centers.
During
center
formation,
B
undergo
transformations
become
mature
function,
exerting
anti-tumor
effects.
Therefore,
targeting
could
provide
new
avenues
for
immunotherapy.
This
review,
combined
current
research
elaborates
relationship
between
aiming
guidance
precise
The Journal of Immunology,
Год журнала:
2023,
Номер
210(2), С. 119 - 125
Опубликована: Янв. 3, 2023
Abstract
The
complement
field
has
recently
experienced
a
strong
resurgence
of
interest
because
the
unexpected
discovery
new
functions
extending
complement’s
role
beyond
immunity
and
pathogen
clearance,
growing
list
diseases
in
which
plays
role,
proliferation
therapeutics.
Importantly,
although
majority
components
circulation
are
generated
by
liver
activated
extracellularly,
activation
unexpectedly
also
occurs
intracellularly
across
broad
range
cells.
Such
cell-autonomous
can
engage
intracellular
receptors,
then
drive
noncanonical
cell-specific
effector
functions.
Thus,
much
remains
to
be
discovered
about
biology.
In
this
brief
review,
we
focus
on
novel
activities
its
“classic
areas
operation”
(kidney
brain
biology,
infection,
autoimmunity),
with
an
outlook
next
generation
complement-targeted
American Society of Clinical Oncology Educational Book,
Год журнала:
2024,
Номер
44(3)
Опубликована: Май 23, 2024
Traditionally
sarcomas
have
been
considered
immunologically
quiet
tumours,
with
low
tumour
mutational
burden
(TMB)
and
an
immunosuppressive
microenvironment
(TME),
consisting
of
decreased
T-cell
infiltration
elevated
levels
H1F1α,
macrophages
neutrophils.
Abstract
Recognition
and
elimination
of
pathogens
cancer
cells
depend
on
the
adaptive
immune
system.
Thus,
accurate
quantification
subsets
is
vital
for
precision
medicine.
We
present
lymphocyte
estimation
from
nucleotide
sequencing
(ImmuneLENS),
which
estimates
T
cell
B
fractions,
class
switching
clonotype
diversity
whole-genome
data
at
depths
as
low
5×
coverage.
By
applying
ImmuneLENS
to
100,000
Genomes
Project,
we
identify
genes
enriched
with
somatic
mutations
in
cell-rich
tumors,
significant
sex-based
differences
circulating
fraction
demonstrated
that
patients
significantly
lower
than
healthy
individuals.
Low
was
linked
increased
incidence.
Finally,
abundance
more
prognostic
5-year
survival
infiltrating
cells.
